These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11689089)

  • 1. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
    Ambo A; Hamazaki N; Yamada Y; Nakata E; Sasaki Y
    J Med Chem; 2001 Nov; 44(23):4015-8. PubMed ID: 11689089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).
    Kitayama M; McDonald J; Barnes TA; Calo' G; Guerrini R; Rowbotham DJ; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):369-76. PubMed ID: 17598088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
    Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
    J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
    Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert DG; Toth G; Borea PA; Salvadori S; Regoli D
    J Med Chem; 2001 Nov; 44(23):3956-64. PubMed ID: 11689082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
    Bigoni R; Rizzi D; Rizzi A; Camarda V; Guerrini R; Lambert DG; Hashiba E; Berger H; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):442-9. PubMed ID: 12070757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
    Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
    Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
    Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
    Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.
    Narita M; Mizoguchi H; Oji DE; Dun NJ; Hwang BH; Nagase H; Tseng LF
    Br J Pharmacol; 1999 Nov; 128(6):1300-6. PubMed ID: 10578145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors.
    Hawkinson JE; Acosta-Burruel M; Espitia SA
    Eur J Pharmacol; 2000 Feb; 389(2-3):107-14. PubMed ID: 10688973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints.
    Zhang C; Miller W; Valenzano KJ; Kyle DJ
    J Med Chem; 2002 Nov; 45(24):5280-6. PubMed ID: 12431054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
    Ichikawa D; Ozaki S; Azuma T; Nambu H; Kawamoto H; Iwasawa Y; Takeshima H; Ohta H
    Neuroreport; 2001 Jun; 12(8):1757-61. PubMed ID: 11409754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships.
    Varani K; Calo G; Rizzi A; Merighi S; Toth G; Guerrini R; Salvadori S; Borea PA; Regoli D
    Br J Pharmacol; 1998 Dec; 125(7):1485-90. PubMed ID: 9884077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
    Varani K; Rizzi A; Calo G; Bigoni R; Toth G; Guerrini R; Gessi S; Salvadori S; Borea PA; Regoli D
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):270-7. PubMed ID: 10543428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of nociceptin and Ro64-6198 activated [35S]-GTPgammaS binding in the rat brain.
    Gehlert DR; Gackenheimer SL; Shaw JL
    Neuropeptides; 2006 Apr; 40(2):95-105. PubMed ID: 16403422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
    Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
    Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phe1phi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as a partial agonist at ORL1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells.
    Olianas MC; Maullu C; Ingianni A; Onali P
    Neuroreport; 1999 Apr; 10(5):1127-31. PubMed ID: 10321496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties.
    Berger H; Bigoni R; Albrecht E; Richter RM; Krause E; Bienert M; Calo' G
    Peptides; 2000 Jul; 21(7):1131-9. PubMed ID: 10998548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.
    Guerrini R; Caló G; Bigoni R; Rizzi A; Varani K; Toth G; Gessi S; Hashiba E; Hashimoto Y; Lambert DG; Borea PA; Tomatis R; Salvadori S; Regoli D
    J Med Chem; 2000 Jul; 43(15):2805-13. PubMed ID: 10956188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.